MorphoSys Announces Clinical Milestone In Antibody Program
Sep 20th 2007Drug InformationCancer
MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced that a HuCAL GOLD-derived fully human antibody against a non-disclosed target molecule in the therapeutic area of oncology has been advanced to a Phase 1 clinical trial. This Investigational New Drug application filing, resulting from MorphoSys collaboration with Novartis, triggers a clinical milestone payment to MorphoSys. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
